The association of homocysteine level with the risk of diabetic nephropathy and diabetic retinopathy in NHANES.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE

Publication: Berlin : Springer Verlag
Original Publication: Berlin : Springer International, c1991-

Diabetic Nephropathies*/etiology ; Diabetic Nephropathies*/complications ; Diabetic Retinopathy*/epidemiology ; Diabetic Retinopathy*/etiology ; Diabetic Retinopathy*/diagnosis ; Diabetes Mellitus, Type 2*/complications; Humans ; Nutrition Surveys ; Cross-Sectional Studies ; Kidney Function Tests/adverse effects ; Risk Factors ; Homocysteine

Aims: To examine the association of homocysteine (Hcy) with diabetic nephropathy (DN) and diabetic retinopathy (DR) in a representative United States population.
Methods: This was a cross-sectional study using data from participants in the National Health and Nutrition Examination Survey 2005-2006. Metrics including Hcy level, urinary albumin to creatinine ratio, estimated glomerular filtration rate, and retinopathy grading were collected. Multiple logistic regression models were employed to assess the association of Hcy with DN and DR.
Results: 630 participants were included in this study. The Hcy level was significantly higher in those with DN and DR than those without DN and DR. Hcy was associated with an increased risk of DN (OR = 1.31, 95% CI 1.18-1.46; P < 0.001). In the fully adjusted model of DN (model II), compared to participants in quartiles 1 of Hcy, the adjusted ORs for participants in quartiles 2-4 were 1.49 (95% CI 0.52-4.26; P = 0.426), 3.81 (95% CI 1.35-10.73; P = 0.015), and 14.08 (95% CI 3.84-51.66; P = 0.001), respectively. Hcy was also associated with an increased risk of DR (OR = 2.260, 95% CI 1.212-4.216; P = 0.014), but this association was non-significant in the fully adjusted model of DR (model II).
Conclusions: In diabetic patients, Hcy was associated with increased risk of DN in a non-linear manner. In addition, Hcy was associated with the risk of DR, but the association was attenuated after adjusting for confounders. In the future, Hcy can potentially be used as an early screening indicator for diabetic microvascular complications.
(© 2023. Springer-Verlag Italia S.r.l., part of Springer Nature.)

Cole JB, Florez JC (2020) Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol 16:377–390. (PMID: 10.1038/s41581-020-0278-5323988689639302)
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract 157:107843. (PMID: 10.1016/j.diabres.2019.10784331518657)
Selhub J (1999) Homocysteine metabolism. Annu Rev Nutr 19:217–246. (PMID: 10.1146/annurev.nutr.19.1.21710448523)
Elias AN, Eng S (2005) Homocysteine concentrations in patients with diabetes mellitus—relationship to microvascular and macrovascular disease. Diabetes Obes Metab 7:117–121. (PMID: 10.1111/j.1463-1326.2004.00376.x15715884)
Tawfik A, Mohamed R, Elsherbiny NM, DeAngelis MM, Bartoli M, Al-Shabrawey M (2019) Homocysteine: a potential biomarker for diabetic retinopathy. J Clin Med 8:121. (PMID: 10.3390/jcm8010121306694826352029)
Pang X, Liu J, Zhao J, Mao J, Zhang X, Feng L et al (2014) Homocysteine induces the expression of C-reactive protein via NMDAr-ROS-MAPK-NF-kappaB signal pathway in rat vascular smooth muscle cells. Atherosclerosis 236:73–81. (PMID: 10.1016/j.atherosclerosis.2014.06.02125016361)
Okura T, Miyoshi K, Irita J, Enomoto D, Nagao T, Kukida M et al (2014) Hyperhomocysteinemia is one of the risk factors associated with cerebrovascular stiffness in hypertensive patients, especially elderly males. Sci Rep 4:5663. (PMID: 10.1038/srep05663250127214092328)
Audelin MC, Genest JJ (2001) Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 159:497–511. (PMID: 10.1016/S0021-9150(01)00531-711730832)
Lei X, Zeng G, Zhang Y, Li Q, Zhang J, Bai Z et al (2018) Association between homocysteine level and the risk of diabetic retinopathy: a systematic review and meta-analysis. Diabetol Metab Syndr 10:61. (PMID: 10.1186/s13098-018-0362-1300832526071377)
Xu C, Wu Y, Liu G, Liu X, Wang F, Yu J (2014) Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta-analysis. Diagn Pathol 9:167. (PMID: 10.1186/s13000-014-0167-y252572414207897)
Mao S, Xiang W, Huang S, Zhang A (2014) Association between homocysteine status and the risk of nephropathy in type 2 diabetes mellitus. Clin Chim Acta 431:206–210. (PMID: 10.1016/j.cca.2014.02.00724534450)
Coral K, Angayarkanni N, Gomathy N, Bharathselvi M, Pukhraj R, Rupak R (2009) Homocysteine levels in the vitreous of proliferative diabetic retinopathy and rhegmatogenous retinal detachment: its modulating role on lysyl oxidase. Invest Ophthalmol Vis Sci 50:3607–3612. (PMID: 10.1167/iovs.08-266719369240)
Dos SNM, Silva AS, de Queiroga EI, Filho JM, Gomes C, Do NR et al (2017) Hypermethylation in the promoter of the MTHFR gene is associated with diabetic complications and biochemical indicators. Diabetol Metab Syndr 9:84. (PMID: 10.1186/s13098-017-0284-3)
Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, Mori K et al (2001) Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 24:533–538. (PMID: 10.2337/diacare.24.3.53311289481)
Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP (2000) Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 23:1816–1822. (PMID: 10.2337/diacare.23.12.181611128359)
Agardh E, Hultberg B, Agardh CD (2000) Severe retinopathy in type 1 diabetic patients is not related to the level of plasma homocysteine. Scand J Clin Lab Invest 60:169–174. (PMID: 10.1080/00365510075004481110885488)
Saeed BO, Nixon SJ, White AJ, Summerfield GP, Skillen AW, Weaver JU (2004) Fasting homocysteine levels in adults with type 1 diabetes and retinopathy. Clin Chim Acta 341:27–32. (PMID: 10.1016/j.cccn.2003.10.03414967155)
Martinez LS, Salazar GM, Rodriguez RM, Baldellou VA (2008) Total homocysteine levels in children with diabetes type 1 Conditional factors. An Pediatr (Barc) 68:264–268.
Luis DA, Fernandez N, Arranz ML, Aller R, Izaola O, Romero E (2005) Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2. J Diabetes Complicat 19:42–46. (PMID: 10.1016/j.jdiacomp.2003.12.003)
Hultberg B, Agardh E, Andersson A, Brattström L, Isaksson A, Israelsson B et al (1991) Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 51:277–282. (PMID: 10.3109/003655191090916151882179)
Centers for Disease Control and Prevention, National Center for Health Statistics. National Health and Nutrition Examination Survey Data (2005) Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/nchs/ nhanes.htm (Accessed 11 Feb 2018).; v. 2022.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AFR, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612. (PMID: 10.7326/0003-4819-150-9-200905050-00006194148392763564)
Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS et al (2016) Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA 316:602–610. (PMID: 10.1001/jama.2016.10924275329155444809)
de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J (2011) Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305:2532–2539. (PMID: 10.1001/jama.2011.861216937413731378)
Early Treatment Diabetic Retinopathy Study Research Group (1991) Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98: 786–806.
Klein R, Klein BE, Magli YL, Brothers RJ, Meuer SM, Moss SE et al (1986) An alternative method of grading diabetic retinopathy. Ophthalmology 93:1183–1187. (PMID: 10.1016/S0161-6420(86)33606-63101021)
Klein R, Meuer SM, Moss SE, Klein BEK, Neider MW, Reinke J (2004) Detection of age-related macular degeneration using a nonmydriatic digital camera and a standard film fundus camera. Arch Ophthalmol 122:1642–1646. (PMID: 10.1001/archopht.122.11.164215534124)
Boushey CJ, Beresford SA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274:1049–1057. (PMID: 10.1001/jama.1995.035301300550287563456)
Pfeiffer CM, Huff DL, Smith SJ, Miller DT, Gunter EW (1999) Comparison of plasma total homocysteine measurements in 14 laboratories: an international study. Clin Chem 45:1261–1268. (PMID: 10.1093/clinchem/45.8.126110430793)
Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH (1993) Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 39:1764–1779. (PMID: 10.1093/clinchem/39.9.17648375046)
Looker HC, Fagot-Campagna A, Gunter EW, Pfeiffer CM, Narayan KMV, Knowler WC et al (2003) Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. Diabetologia 46:766–772. (PMID: 10.1007/s00125-003-1104-x12774164)
Ma L, Liu Q, Jiang Y, Zhao H, Zhao T, Cao Y et al (2019) Genetically elevated circulating homocysteine concentrations increase the risk of diabetic kidney disease in Chinese diabetic patients. J Cell Mol Med 23:2794–2800. (PMID: 10.1111/jcmm.14187307296776433716)
Gupta P, John D, Rebekah G, John SS (2018) Role of hyperhomocysteinemia in proliferative diabetic retinopathy: a case-control study. Indian J Ophthalmol 66:1435–1440. (PMID: 10.4103/ijo.IJO_350_18302498286173030)
Chen X, Zhang X, Nie Y, Gong Z, Sivaprasad S, Fung AT et al (2022) Circulating level of homocysteine contributes to diabetic retinopathy associated with dysregulated lipid profile and impaired kidney function in patients with type 2 diabetes mellitus. Eye (London, England) Online ahead of print.
Huang E, Kuo W, Chen Y, Chen T, Chang M, Lu M et al (2006) Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clin Chim Acta 366:293–298. (PMID: 10.1016/j.cca.2005.10.02516343469)
Sun J, Xu Y, Zhu Y, Lu H, Deng H, Fan Y et al (2003) The relationship between MTHFR gene polymorphisms, plasma homocysteine levels and diabetic retinopathy in type 2 diabetes mellitus. Chin Med J (Engl) 116:145–147. (PMID: 12667409)
Yang G, Lu J, Pan C (2002) The impact of plasma homocysteine level on development of retinopathy in type 2 diabetes mellitus. Zhonghua Nei Ke Za Zhi 41:34–38. (PMID: 11940295)
Huijberts MS, Becker A, Stehouwer CD (2005) Homocysteine and vascular disease in diabetes: a double hit? Clin Chem Lab Med 43:993–1000. (PMID: 10.1515/CCLM.2005.17416197287)
Weiss N (2005) Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab 6:27–36. (PMID: 10.2174/138920005299735715720205)
Li Y, Zhang H, Jiang C, Xu M, Pang Y, Feng J et al (2013) Hyperhomocysteinemia promotes insulin resistance by inducing endoplasmic reticulum stress in adipose tissue. J Biol Chem 288:9583–9592. (PMID: 10.1074/jbc.M112.431627234177163617262)
Au-Yeung KKW, Woo CWH, Sung FL, Yip JCW, Siow YL, Karmin OK (2004) Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 94:28–36. (PMID: 10.1161/01.RES.0000108264.67601.2C14630727)
Muzurovic E, Kraljevic I, Solak M, Dragnic S, Mikhailidis DP (2021) Homocysteine and diabetes: role in macrovascular and microvascular complications. J Diabetes Complicat 35:107834. (PMID: 10.1016/j.jdiacomp.2020.107834)
Long Y, Nie J (2016) Homocysteine in renal injury. Kidney Dis (Basel, Switzerland) 2:80–87.

201804010038 Guangzhou Science and Technology Program key projects; 3030901006102 Guangzhou Science and Technology Program key projects; 2020A1515010276 Natural Science Foundation of Guangdong Province; 82000901 National Major Science and Technology Projects of China; 2018Y9087 Fujian Province Key Laboratory of Special Aquatic Formula Feed (Fujian Tianma Science and Technology Group)

Keywords: Diabetes complications; Diabetic nephropathies; Diabetic retinopathy; Homocysteine

0LVT1QZ0BA (Homocysteine)

Date Created: 20230330 Date Completed: 20230522 Latest Revision: 20230522

20231215

10.1007/s00592-023-02075-2

36997800